 PhaseBio Pharmaceuticals Inc NASDAQ: PHAS has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding. 